C-CBKUVascarta
transdermal delivery, curcumin, linker chemistry
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CBKU
C-CBKUC-CBKUtransdermal delivery, curcumin, linker chemistry
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Dr. Scott Braunstein Joins Vascarta Advisory Board | Vascarta Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … J. P. Morgan Asset Management and Portfolio Manager of their Global Healthcare Fund. -Practicing physician at the Summit Medical Group and Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. We look forward to benefitting from Dr. Braunstein's strategic direction to accelerate the commercialization of Vasceptor® and bring this groundbreaking therapy to patients with sickle cell disease, osteoarthritis, and other inflamm
Vascarta's Transdermal Curcumin Gel Shows Promise in Sickle Cell Disease | Paul Sklar posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o
Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
%PDF-1.6 %���� 84 0 obj > endobj 106 0 obj >/Filter/FlateDecode/ID[ ]/Index[84 34]/Info 83 0 R/Length 106/Prev 126442/Root 85 0 R/Size 118/Type/XRef/W[1 3 1]>>stream h�bbd```b``�"����r ���~�̩`�`��d�[��A0) &��H�}`] R� D&�I���`3�@�[:������ �� ��$�@W0�lJ endstream endobj startxref 0 %%EOF 117 0 obj >stream h�b```�� � >/Metadata 7 0 R/PageLayout/OneColumn/Pages 82 0 R/StructTreeRoot 12 0 R/Type/Catalog>> endobj 86 0 obj >/Font >/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 87 0 obj >stream hޤVmo�0�+�B����&�I�XG��l �!t��蒪 ��{�v۵�ZYv����� .Ӻf�ם����8� �+?+g�B5�� … 899c91e-2ea9-4274-bc33-0d2eec9d71d6 uuid:9ccaa601-fe57-476a-b65e-23bf103133c0 8 application/pdf Larry Prince Adobe PDF Library 25.1.250 D:20250514142644 endstream endobj 8 0 obj >stream h0R0P���w�/�+Q0���L)��0 )�Ic� RY�� ���Zlg`j endstream endobj 9 0 obj >stream h�l�� �0�Wɭ��6���� /�PP�&+Ɵ��)ҷ7��0���ƌ��"[u�����g5��@���v��?�w�� ���B{����Bq�˜������8�>�� a�=��M�/@L(vDb$�d[�! ���+ք�3H� +]C:�+T���(�vؑ�`����I1�2�� Ƈ���W����%��/L� endstream endobj 10 0 obj
%PDF-1.6 %���� 2 0 obj >stream x�켉cS��? BH��W�dz�U���zH�H�P=��Ń�Ci���!� �K?�N-@�;ЪS�l��S�)�)�zJ9%�O ��S����:�� �禟�0z�Oe�4�x��� �r���;O������S {�G �>:�(����G�GK�� �q����#eG� )9��H�#�G|G G���:|��w �w���;� ��?wx�� �|8�p����' ��v!4y|�Mn1���Bξ���K�I�J�$��~B����?�T���R��]@��gӠl����$l�*�g�%��&;Εc�,����&R��eZe�s/�?_�N�38���18ZX�W�������ҁ~, �g���.�Ӛ�і�1��6-��j��σMg{�mV+BV6N�� 3�9�,Z��pע�wh)Z�V�'�z���X|��A�Dw���r��� z����~Eg�3`���� h �V�q�]4 ���A ����h?� M@ �� zMD?�{���#tMB?�S�N4MFS�t4 ]�֠��L4�B�� h�݄N���t3��G��v�4Z�n����~B;���!L0�y,� �"~?� ŏ�ԈE,a … isease PDFlib+PDI 9.0.7p3 (C++/Win64); modified using iTextSharp 4.1.6 by 1T3XT application/pdf 10.1093/pnasnexus/pgaf053 en Oxford University Press Targeting sickle cell pathobiology and pain with novel transdermal curcumin Yugal Goel Mya A. Arellano Raghda T. Fouda Natalie R. Garcia Reina A. Lomeli Daniel Kerr Donovan A. Argueta Mihir Gupta Graham J. Velasco Richard Prince Probal Banerjee Sirsendu Jana Abdu I. Alayash Joel M. Friedman Kalpna Gupta DOI: 10.1093/pnasnexus/pga
%PDF-1.4 %���� 16 0 obj > endobj xref 16 48 0000000016 00000 n 0000001559 00000 n 0000001670 00000 n 0000003151 00000 n 0000003487 00000 n 0000004016 00000 n 0000004735 00000 n 0000004770 00000 n 0000004883 00000 n 0000004994 00000 n 0000005344 00000 n 0000005738 00000 n 0000006240 00000 n 0000006802 00000 n 0000006906 00000 n 0000007486 00000 n 0000008138 00000 n 0000009225 00000 n 0000009549 00000 n 0000010081 00000 n 0000010164 00000 n 0000010647 00000 n 0000011221 00000 n 0000011537 00000 n 0000011921 00000 n 0000012999 00000 n 0000013922 00000 n 0000014938 00000 n 0000015424 00000 n 00000 … ��EF��q�rf� CįQ9ZY�$r!���6m �)�4� ��V�9�k�J�$#�� Fь�X��٥�C��p�[��ģ)C���S�;rFP#�I�m�K�G ɺ��z���j>>��X�9,�ZL-j��Ib�k��ȉ8�˚?v�t���� �x������P�IO}�_ay@ ��:����|Ve�6�����ubd/e�3 T� Sؓ�7X����?MM�!���Լu�O��t����P Cbt;���i����ް��a��@gW��#�@��4c�9.D���o� z2>M�5��i�~�u0� �q�s �wQ�9�ǸLt��삟�Mz)>���kɝ���I�;���io�"���U)��]$Y���L >� $����$T����:gUo$���UK���,�C�`sCMAJMÄ��K��C(��g]���ٮ9�s�U�G�0?����L�5��� �QM%��0O�l��5&���`�Ƒ 1,��x�'���{��k+�mY�}��� … �N�!�XH#��ⅺ��(���!�p�? �E:���r�h�e��]U�\�j:Ac�H*ꮑ��_Z'U���%�A�c>�R�4,�rfP2G����筑�+.pj�e�ħ�si���ߧsR?��yT����V邚g�?bS���L>r� Z��P�J�:`Hf���s����_�]`D�K�! �y]�`��?�F�M�2�G�������I/�nIg���^s��q&�r�RC��� %�\�\D@�t`=D �q��r !� %�w�nC:4�L�c�h���� ����j�Aw��n�#.aߜ ���A���i �Z�.uK,����� f�[� S��!�8�F�;�E/���m5 E]��I�����-��c6���s��ڤ)�!p�b��]Og�'kN�:�u���W-"D$��mݝ��{s�[�Rk�$=c��{C�M���� ���}T��*y+���7)Zf���+�MJ�ԅ�*U� i�"F&~���߲�b b�; �� … �o�X�e��_a�5a\N�k�E �3�c��\^i4�65����!�gV�5k4 o��i?��e����!e�#A��aϑz3�R�Rfp%X�_O3�+U$�f�Vր���N1/w �l�s�^�$LyI�,q�N�|YWq���e���� �� C�_�f��\D\� �� M��.��X�)I�����y�Y͑Y��R�bf�n��� E$�k��u��4H�Q"��Ϟ��|���r0���ઙ����� +����� ��8_���c}� -h�G� ���^zIq�o�mPg�lH�6^.+@��a��穔�W������d��1>a�Z��& ��u=%g]�oq�Hy�q� �+ ���ͦ=Ge2�۷�9��~�C�� � �uHͅ��M����kos��8R�v�D���� kUmq��.�2/ ���ՠ2�'�S� X���階KF�oq�*$�}U� �h=P���R��{��Eg�!=a�����,�U�Z"�v�� 7�� … 60c 2021-02-10T15:51:04+02:00 Adobe Illustrator 24.0 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:a5656c35-5cf7-44c1-a461-dd6b321a8ce4 2023-02-14T11:00:27-05:00 Adobe Illustrator 26.5 (Macintosh) / application/pdf GettyImages-1310296663-rev Adobe PDF library 16.07 1 True False 5024.297900 50
Joel Friedman on Ancient Remedies for Vascular Healing Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us 201-572-2484 Make a call [google-translator] Joel Friedman: Harnessing An Ancient Remedy Einstein Magazine Winter-Spring 2023 Home Scientific Papers Joel Friedman: Harnessing An Ancient Remedy Einstein Magazine Winter-Spring 2023 Marketing Team January 2025 Scientific Papers If you had wandered into Einstein’s Falk Center seven years ago, you might have overhead Jo
Vascarta Announces Completion of Phase 1 Clinical Trial of VAS-101 for the Treatment of Osteoarthritis Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
7 Key Benefits of Anti-Aging Drug Pre-Clinical Research | Vascarta Inc. Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us 201-572-2484 Make a call [google-translator] 7 Benefits of Anti-Aging Drug Pre-Clinical Research Today Home Clinical Research 7 Benefits of Anti-Aging Drug Pre-Clinical Research Today Marketing Team June 2026 Clinical Research There is something quietly remarkable happening inside research laboratories around the world. Scientists are not just stud
Full Schedule Skip to main content Toggle navigation Login Search Home Full Schedule NOTE: All events are in Eastern Daylight Time Zone. Home Full Schedule Click Here for Speaker Ready Room Hours All Days Thu, Jun 4 Fri, Jun 5 Sat, Jun 6 Sun, Jun 7 Full Schedule Type here to filter the list Thursday, June 4, 2026 7:00 AM - 5:00 PM ET Registration Open 7:00 AM - 5:00 PM ET Registration Open Location: Level 2 Prefunction - East Building 7:00 AM - 5:45 PM ET Grant Writing Institute (GWI) 7:00 AM - 5:45 PM ET Grant Writing Institute (GWI) Location: 253AB Sponsored By 1:00 PM - 5:00 PM ET Up … PM - 4:00 PM ET Audience Poll Location: 250AB 4:00 PM - 4:15 PM ET Wrap Up and Prize Drawing Location: 250AB Friday, June 5, 2026 8:00 AM - 9:00 AM ET Attendee Breakfast 8:00 AM - 9:00 AM ET Attendee Breakfast Location: Atlantic Prefunction - Level 3 8:30 AM - 7:30 PM ET Registration Open 8:30 AM - 7:30 PM ET Registration Open Location: Level 2 Prefunction - East Building 9:30 AM - 11:00 AM ET Special Symposium: Advancing Biomarkers in Sickle Cell Disease: Regulatory Pathway … Bernal – UCLA Co-Author: Candice Deler – Candice's Sickle Cell Fund Co-Author: Duc T. Nguyen, M.D., Ph.D. – Baylor College of Medicine Co-Author: Diane Wilkins – UT McGovern School of Medicine Co-Author: Jemimah O. Frempong, B.A. – Children's Hospital of Philadelphia Co-Author: Kenneth Nobleza – Baylor College of Medicine Co-Author: Melanie M. Aviles – Jacobi Medical Center Co-Author: Noe Gonzalez – Texas Children's … 0 PM ET Strengthening Sickle Cell Disease Advocacy Through Ambassador Training, Fellowship Development, and Policy Mobilization Location: 253AB Presenting Author: Dagmawit Teka, MPH – Sick Cells Presenting Author: Melissa Akinlawon, MA – Sick Cells Co-Author: Ashley Valentine, MRes – Sick Cells Co-Author: Jamie Dornfeld, MBA – Sick Cells Community / Public Engagement Designed by Cadmium | Technical Support © Copyright 2026 Cadmium. All Rights Rese
Vascarta | Availability and Directions for Use | Richard Prince LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Priva
Patented transdermal drug candidate from Vascarta may offer a convenient & cost-effective way to treat sickle cell disease | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Virtual Press Office: Trade show news, exhibitor news, online press kits --> Send a News Release --> Blog For Journalists News Solutions Resources --> --> Overview Marketing Public Relations IR & Compliance Agency All Products Contact Us Journalists Blog Become a Member Send a Release --> Order a Press Kit News Solutions Resources --> Search Contact Us +1 973-783-7787 option 0 Home Products Event Organizer Services News Releases Events Press Services Overview Marketing Public Relations IR & Compliance Agency All Products --> News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 … os is pleased to announce its... Nov 13, 2025 Amorepacific Named CES Innovation Award Honoree for Advanced Electronic Skin Platform CES Exhibitor News releases, photos and supporting content - Co-developed by Amorepacific and MIT, Skinsight™ receives recognition as the company's seventh consecutive win at CES - Applied in substantiating the efficacy of a Sulwhasoo product, with... Nov 13, 2025 Save the Date and Call for Participation for ASES SOLAR 2026: The National Solar Co … 2025 Commvault Honors the Fearless Few - Announcing Global Partner of the Year Award Winners at SHIFT NYC Virtual Press Office and PR Newswire: General Trade show news HPE, CDW, Softcat, and Logicalis Australia lead the 2025 Fearless Awards announced at SHIFT NYC NEW YORK, Nov. 12, 2025 /PRNewswire/ -- SHIFT 2025 – Commvault (NASDAQ: CVLT), a leader in unified... Nov 12, 2025 Assurified Advances Risk Transformation Platform Ahead of OPTECH 2025 Virtual Press Office and PR Ne … rvices and winner of the 2023 Microsoft Security Services Innovator of the Year award, today... Nov 12, 2025 Proficio Wins Three Prestigious Awards in the 2025 Top InfoSec Innovators by Cyber Defense Awards Virtual Press Office and PR Newswire: General Trade show news Proficio®, a global leader in extended detection and response (XDR) services, has been honored with three major awards in the 13th annual Top InfoSec Innovator Awards for 2025 presented by Cyber... Nov 12, 2025 … ajor update introduces new features while maintaining Helm's role in Kubernetes application management Key Highlights Helm 4, the first major update in six years to the Kubernetes package... Nov 12, 2025 The International Beverage Dispensing Equipment Association Announces its 2026 Annual Conference: Innovation, Connection, and Collaboration Set
%PDF-1.4 %���� 1 0 obj > endobj 6 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 7 0 obj > /Font 31 0 R >> /MediaBox [0.0 7.9200063 612.0 799.92] /Annots [32 0 R] /Contents 33 0 R /StructParents 0 /Parent 2 0 R /Tabs /S /BleedBox [0.0 7.9200063 612.0 799.92] /TrimBox [0.0 7.9200063 612.0 799.92] /CropBox [0.0 7.9200063 612.0 799.92] /Rotate 0 >> endobj 8 0 obj > /Font 38 0 R >> /MediaBox [0.0 7.9200063 612.0 799.92] /Annots [39 0 R] /Contents 40 0 R /StructParents 1 /Parent 2 0 R /Tabs /S /BleedBox [0.0 7.9200063 612.0 799.92] /TrimBox [0.0 7.9200063 612.0 7 … h�+o8� �)Ǖ������M��ۃ���'��T���(�FN�G���h�ǧ� 3T� *��V�\ ����J3���"]W�� �$u�rFp�Q)Ek} J�и.��a#��Fk�3����c+{�[ܦ~Rd'�c r�o�����$��KxH1M���ך*.uvO������Q� S�M6�&�� �vV���_�w�����6��wȊc$� �ι� �n�o��:���ZO����W�k�^y�3�Cg#�+H���/��m��&sRR��mezu�'�&@Nns��Yݩ��������(ũ+�����{��M%`�[�� rg� �R����/yoo���2�8��ʳK e��ڢ��.���_#jN��]��z ��溊�t倇l����EҌ�kY��ϱO�ӹ��_� ~#[Zh��D�u�`� /�� �һp�ϩ��h��_)���ϝ]F�w��6/� ����x�v`���' ��y�U�NT����z_����j��,E� ��rY5����*[5���5���
Vascarta commences Proof of Concept Phase 1 clinical study of VAS-101 in sickle cell disease in the United States Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
SPDX-License-Identifier: 0BSD --> Vérification de la connexion... Les robots IA perturbent le Web, JavaScript est nécessaire pour accéder à cette page. protégé par haphash
Stock Quotes - Welcome, guest! - Log on | Join ($$) VF "How To" Guide Welcome, guest ! Learn about guest access The Coffee Shop BDC Investor Canada Stock Channel CDx3 Investor CEF Channel ChartZero Contrarian Outlook Dividend Channel Energy Stock Channel ETF Channel Holdings Channel Market News Video Metals Channel Portfolio Channel Preferred Stock Channel Stock Options Channel The Online Inve
All Clinical Trials & Medical Discoveries News and Press Releases from PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All V … tralia SK bioscience announced that it has submitted a Phase 1/2 clinical trial application in Australia for GBP511, a universal coronavirus vaccine... Oct 15, 2025, 08:00 ET Ouro Medicines Announces Expansion of Clinical Development for OM336 in Sjögren's Disease and Idiopathic Inflammatory Myopathy Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated diseases, today... Oct 15, 2025, 08:00 ET OncoHost to … uot;Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China... Oct 14, 2025, 06:00 ET Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced that it will be presenting two rapid-fire... Oct 14, 2025, 05:00 ET EVOQ Therape … o rapid-fire... Oct 14, 2025, 05:00 ET EVOQ Therapeutics Awarded $2 Million NIH Grant to Advance Therapies to Treat Celiac Disease - An Autoimmune Disease Impacting 2.4 Million Americans EVOQ Therapeutics, Inc. (EVOQ) a biopharmaceutical company dedicated to the treatment of autoimmune diseases, announced today the receipt of a $2... Oct 14, 2025, 03:30 ET First patient treated with Leqembi® (lecanemab) in the Nordics BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced t … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 45 --> 45 46 --> 46 47 --> 47 48 --> 48 49 --> 49 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is sele
SCCAPE 2026: Sickle Cell Care Coordination for Achieving Patient Empowerment - VCU Health Continuing Education - Continuing Education (CE) Now in its 7th year, SCCAPE is a four-day, interdisciplinary conference designed for physicians, physician assistants, nurses, social workers, psychologists, pharmacists, community health providers, patients, and their families. With tiered learning pathways for novice and advanced participants, SCCAPE covers Sickle Cell Disease pathology and treatments, behavioral and mental health, transition from pediatric to adult care, equity and structur … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … nbsp; Substitution requests must be made at least 3 days before the conference. Submit requests via email to [email protected] with the original registrant’s name and the substitute’s information. The substitute attendee must be in the same registration tier, or any price difference must be paid. Force Majeure In the event of conference cancellation or postponement due to unforeseen circumstances (e.g., natural disasters, pandemics), participants will have t … ify participants promptly if such circumstances arise. o Transfer Registration: Apply the fee to a future SCCAPE event. o Partial Refund: Receive a refund, less a 15% non-refundable administrative fee and any unrecoverable expenses. Contact Information For questions regarding refunds, cancellations, or substitutions, please contact [email protected] . Accreditation In support of improving patient care, VCU Health Continuing Education is jointly accredited by the A … ntinuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 23.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. VCU Health Continuing Edu
Einstein Holds Inaugural Start-Up Showcase | Montefiore Einstein Skip to main content Navigation focusTarget?.focus()); } " :style="topBarPadding > 0 ? `--top-bar-padding: ${topBarPadding}px` : {}" > $refs.btnHamburgerMenu?.focus())" @mf-hamburger:return-focus.window="$nextTick(() => $refs.btnHamburgerMenu?.focus())" > Close menu ({ input: "" })" x-init="$watch('input', (val) => { input = val || ''; $dispatch('mf-text-input:changed', input); })" :class="{ 'mf-text-input--filled': (input || '').length > 0 }" > Search terms * 0" @click.prevent="$dispatch('mf-text-input:reset', input); … e faculty members, primarily awardees of the College of Medicine’s Acceleration Fund, showcased their promising discoveries to potential investors and partners. The 15 posters covered a range of opportunities, including research targeting chronic diseases, such as diabetes and cancer, as well as age-related neurodegeneration. These posters will be displayed on Main Street in Forchheimer from Dec.1 to 11. Among the attendees was Noah Jacobs, a second-year M.D.-Ph.D. student wh
Full Schedule Skip to main content Toggle navigation Login Search Home Full Schedule NOTE: All events are in Eastern Daylight Time Zone. Home Full Schedule Click Here for Speaker Ready Room Hours All Days Thu, Jun 4 Fri, Jun 5 Sat, Jun 6 Sun, Jun 7 Full Schedule Type here to filter the list Saturday, June 6, 2026 7:00 AM - 8:00 AM ET Attendee Breakfast 7:00 AM - 8:00 AM ET Attendee Breakfast Location: Atlantic Prefunction - Level 3 7:00 AM - 8:00 AM ET Product Theater & Breakfast 7:00 AM - 8:00 AM ET Product Theater & Breakfast: Bridging Polymerization, Inflammation, and Innovation in Sickle C
%PDF-1.6 %���� 138 0 obj > endobj 168 0 obj >/Filter/FlateDecode/ID[ ]/Index[138 55]/Info 137 0 R/Length 133/Prev 142741/Root 139 0 R/Size 193/Type/XRef/W[1 3 1]>>stream h�bbd```b``�� 3@$�*�� fk�I10&o�H��`�3��`�7`�0X� �] ���. �i?X�خ.i�D�LfT��Z"�@��C��)�R ��5f`�\l����z^J�� endstream endobj startxref 0 %%EOF 192 0 obj >stream h�b``�```�������� Ȁ�@1V� �Tz�$ݔ'�~��(t�'F� J ��`�@����H��,X�����CB�UB���!�qAc���/�b lc�w�dZ� �q���z!��h��'&p�8@��b`����LG�k���s�4#�(�', endstream endobj 139 0 obj >/Metadata 12 0 R/PageLayout/OneColumn/Pages 136 0 R/St … 91a1703-fcc6-4d85-aa39-dd2163939f52 uuid:b64df533-e282-4fbc-8ead-1114370f14c9 6 application/pdf Joel Friedman Adobe PDF Library 25.1.40 D:20260409221721 endstream endobj 13 0 obj >stream h�246S0P���w�/�+Q0���L)�641�)��X��ʂT�����b;;�9 U endstream endobj 14 0 obj >stream h�l�� �0�W����M�jU�P,=����Y1j���H��TD >/Filter/FlateDecode/ID[ ]/Info 137 0 R/Length 103/Root 139 0 R/Size 138/Type/XRef/W[1 3 1]>>stream h�bb&F�#Y L �� ��D2��H5��F �(� f��H�&0[Dr�U2������S�� �����
neflamapimod (VX-745) / CervoMed neflamapimod (VX-745) / CervoMed - LARVOL DELTA Home Next Prev 1 to 25 Of 189 Go to page 1 2 3 4 5 6 7 8 June 18, 2026 CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042 (The Manila Times) - "The patent is designed to protect the Company’s strategy targeting the treatment of patients with pure DLB. Currently, there are no approved treatments for DLB in the United States or European Union." Patent • Dementia • Lewy Body Disease Print Email More sharing Reddit StumbleUpon Delicious June 10, 202 … with the FDA on a proposed Phase 3 trial design to support a potential New Drug Application for neflamapimod in DLB in November 2025 and with other global regulators during the first quarter of 2026. Based on FDA feedback, CervoMed plans to initiate a single, global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of neflamapimod in approximately 300 patients with DLB, subject to available funding." New P3 trial • Dementi
Advancing Therapeutic & Diagnostic Research | Vascarta It is a long established fact that a reader of a page when looking at its layout. Book Now Error: Contact form not found. 201-572-2484 [email protected] Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us Search for: Search Clinical Research Home Clinical Research Vascarta is currently clinically focused on two conditions with great unmet medical need: Sickle Cell Disease and Osteoarthritis. The following tab … ats was intentionally damaged causing leakage in the blood vessel. However, the application of Vasceptor® prevented the blood vessel damage and leakage: Vasceptor® reduces blood vessel damage and leakage Directly measuring the blood pressure of rats treated with Vasceptor® shows a substantial reduction in blood pressure lasting for hours. If this finding ultimately holds in human beings, there would be a large benefit to reducing blood pressure without unwanted side effects. … t; 0.01; ***††† P < 0.001 The PNAS Nexus publication also describes that the application of Vasceptor® significantly deactivated granulated mast cells (MC), which are significant indicators of inflammation and contributors to chronic pain. Sickle Mice Treated With Vasceptor® Have Fewer Degranulated Mast Cells (MC), Indicators of Inflammation and Contributors to Chronic Pain Statistical Significance levels: *P < 0.05; **P < 0.01; ***P < 0.001. Nerve damage is anoth … nother characteristic of SCD. The PNAS Nexus publication further describes that application of Vasceptor® reverses nerve damage which was induced in the treated mice by applying TNF-α+hemin (T + H). As shown below, when T+H is applied, the number of nerve (neurite) connections (intersections) is greatly reduced. However, usage of Vasceptor® (“Curc”) restored the number of nerve connections, even when combined with the nerve damaging T+H. Vasceptor® Reverses Nerve Damage in Si
%PDF-1.4 %���� 1 0 obj > endobj 7 0 obj > endobj 2 0 obj > endobj 3 0 obj > stream FSCDR Prospectus 2026 REVISED 020426 FSCDR Prospectus 2026 REVISED 020426 endstream endobj 4 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 8 0 obj > /Font 43 0 R >> /MediaBox [0.0 7.9200063 612.0 799.92] /Annots [44 0 R] /Contents 45 0 R /StructParents 0 /Tabs /S /Parent 2 0 R /BleedBox [0.0 7.9200063 612.0 799.92] /TrimBox [0.0 7.9200063 612.0 799.92] /CropBox [0.0 7.9200063 612.0 799.92] /Rotate 0 >> endobj 9 0 obj > /Font 60 0 R >> /MediaBox [0.0 7.9200063 612.0 799.92] /Annots [61 0 R 62 0 R 63 0 R 64 0 R … ��.zr�ۓZ=l��� �>��7�~�� ��_���� Y�-������c � �=�/����x��Z%�E��V��\�{�� rFp�2 ����d��T��R���������=e��1����J_Y�'�%� ^j��I��9J�H�x� �5��Bt���w����ս|��v��9�ĥK �8�ʔm��w����>j���sE�����%���l��x\ɖ-�x�z��p��4g�&��%�����8����� O.�c(ҿ3���N1QWwV�m�>g;�R;{O� ���w$w��H˷F��������bVt�4�wwv�z�����ps�NJj˦�{w][Z��o |R�ǀ#���e�jr�tW����J(`0p�Wo�|���&�տ�����nw����Jx�B�n���O�ג��kyYh���^���D���������\�{C�bT�%-�!�S�8�X�ӿ +\x^�o&�ccoa�] om�2�K"��#j��7�*tjת�$��%������� … vߖ���td]�;ņJB�\�֪�GW�2\�U���i�Ӓ���kt��ԡ.�� �P�$���ߡ�u[W����N��7s8����K�K�� RFP���n�g����(���ԞI���_-��V�G�H's���8��5� Ԡܥ�{��}�0��>x�饿��ĺ����5%Fs���O�O�T���Ȋ����=n�~!0[$r��PpBs���p�MoӢ��M8�9;���������G��Xa�c t�u�X�I;kk;��>��Ҕ K8����o�px�2��/ѝ��'�{t�qO���kh��;�Gj����E[�Z���,E�E�5�eA����3�c�jjPj�-_��i~�F���� ֝u��R����b�(�z0�98 �����N�7�%�����%�r���~�/��ռC#� I�rpB�A9'�ʟ+�|�%'�t��9'�];+�m������Zk�J7�F���3����\�|����˿q���Q���~���r�~"��_.�; 0 % ��m�N����� … E2#Q}o ��T�����0�����0SjZ�6��f��������&h )UuYՍ;�g�ϟh�t������/��ܸ��z�\ۤ XƟ̀frfp�̸�63��/�~�M�z��/Н/#3~:F1�^z��imc��r�lƹc~&ӎ����j�q��C�|����_�h���+�u�Y�U�ĵ/m �'�w�`����|� �l�sЧ�X �ԅ�}SW����q�� q�����&�e�o�Y�=��� �V�6���V�c����+Ӛ'�n}Vǯ�}���η���!D�|0����?^�p��w,Yұli��e�V,�Z��{���K�,_�x�����WEl�H-�k(�Xt�$O I%I�!�r�,��в$����G�UG�"��I )ӹ�2�HR�D�8R��`r�e 9�Kq 2���/��FH�e�r}�]�|ͪ� BI �똷�sѢGKw-_ O~5z��+� �$"�7r5�Qk���E� �X�Xq9�J# ?9H�\D(�"��B��R]D� � … �8� v�+�8�c^Aǽ�z � ��w� �A'}�t��O�� �ޡ�ޡ^�ޡ�`� k�0�9�>�� ������� �s�Rfp�i��Ӂ ���r�L��4h��i�J�:ؚ�R�u�h U7 ^]����ld �,���gi�Y,Y(�c����^��G=�Q�zԣ ����2j����*���b�c,oQX�N���L+�LKl�e霍�O�t�Ƹ� f�A�� �.��M>K�E�G"Y�h�R0Z�/.��9�7D��!ȝ��(��3w����p�bq�L�76͟�H�&���'��5����m�r�z�`�h`��7����䞞Ķ>Bc#������!��V(܅���-�]c����Y2�8
Processing blood samples for sickle cell disease trials | Patrick Hines posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agr … technologies, #ASC35 is expected to have its Investigational New Drug ( #IND ) application submitted to the FDA in the second quarter of 2026. ------------------------------------------------------------- Stay up to date with everything obesity through my newsletter 😊 https://lnkd.in/dncNKh3R 17 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Jessica Zhe Li 8mo Edited Report this post 🧬 Weekly Biopharma Roundup (Oct 6–12,2025) A high-impact we … Co. Ltd. ’ recombinant humanized monoclonal antibody MIL62 has had its new drug application accepted, likely targeting Primary Membranous Nephropathy (PMN). 🔬 About MIL62 In-house developed 3rd-gen anti-CD20 First clinical trial: Feb 2016 First clinical approval: Oct 2016 First NDA submission (neuromyelitis optica): May 2025 🏥 Phase III Progress MIL62’s Phase III trial in PMN is advancing as a multicenter, randomized, controlled, open-label study evaluating its efficacy and
All Pharmaceuticals News and Press Releases from PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery O … bekannt, dass die U.S. Food and Drug Administration (FDA) die Biologics License Application (BLA) für Waskyra... Dec 10, 2025, 17:31 ET Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic cancer... Dec 10, 2025, 16:30 ET Citius Onc … que la U.S. Food and Drug Administration (FDA) a approuvé la Biologics License Application (BLA) pour... Dec 10, 2025, 12:43 ET Azenta Authorizes $250 Million Share Repurchase Program Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may... Dec 10, 2025, 11:29 ET Voranigo® (vorasidenib) de Servier recibe premios Prix Galien en varias regiones Servier, grupo farmacéutico internacional indepe … Dec 10, 2025, 08:00 ET Diakonos Oncology Awarded Multi-Million-Dollar Research Grant by the Cancer Prevention and Research Institute of Texas to Advance DOC1021 in Refractory Melanoma Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive... Dec 10, 2025, 08:00 ET Expression Therapeutics Appoints Industry Veteran Dr. David Townson as Chief Executive Officer Expression Therapeutics, In … the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for... Dec 10, 2025, 07:12 ET Fondazione Telethon Announces FDA approval of Waskyra™ (etuvetidigene autotemcel), a Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome Fondazione Telethon announced today that the U.S. Food and Drug Administrati
Curcumin skin gel shown to improve heart health in SCD mice Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About sickle cell disease Toggle menu: About sickle cell disease What is sickle cell disease? Causes Symptoms Diagnosis Vaso-occlusive crisis Treatments Approved treatments Experimental treatments Non-drug treatments Living with Toggle menu: Living with Living with sickle cell disease Community Toggle menu: Community Columns Shaniqua’s Sickle Chronicles — Mary Shaniqua The Sickle Cell Crusader – Oluwatosin Adesoye Sickle Sagas — Dunstan Nicol-Wil
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
prnewswire – Free Press of Jacksonville About Us Media Kit Subscribe Submit Photo Fictitious Name Event Submission Around Town Church News Contact Us Instagram Facebook Twitter rss feed Home News Community Local National International Education Business prnewswire Entertainment Crosswords Sudoku Politics EDITORIALS Lifestyle Health Advice Book Reviews Religion Urban Traveler Greek Life Obituaries Sports Calendar Photos Breaking news [ June 27, 2026 ] Hey, Cousin: What I Saw On Juneteenth At Andrew Jackson’s Plantation Editorials [ June 27, 2026 ] 50 Years Later, is ‘Roots’ on the Wrong S … for: Home prnewswire prnewswire Advertisement WE APPRECIATE YOU DONATING TO OUR FUND THAT SUPPORTS THE FUTURE OF JOURNALISM & THE INDEPENDENT PRESS (Please enter your Payment methods data on the settings pages.) Video Of the Week Twitter Tweets by @JacksonvilleFP About JFP JFPress provides local, state and national news. Recent Posts Hey, Cousin: What I Saw On Juneteenth At Andrew Jackson’s Plantation 50 Years Later, is ‘Roots’ on the Wrong Side of History? TPS: Supreme … Barack Obama Breaks His Silence on His Health Menu About Us Media Kit Subscribe Submit Photo Fictitious Name Event Submission Around Town Church News Comments About Us Media Kit Subscribe Submit Photo Fictitious Name Event Submission Around Town Church News Copyright @ 2026 Website Design by No Regret Media
Vascarta Partners with CUNY to Enhance Chemotherapy Efficacy and Safety - Global Pharma --> Toggle navigation HOME ARTICLES INTERVIEWS EVENTS APPOINTMENTS ENEWSLETTERS MAGAZINES BLOG MEDIAKIT ABOUT US CONTACT Search NEWS ABOUT > Biotechnology Clean Rooms Clinical Trials Consultants Digitalization Drug Discovery & Development Engineering Global Pharma Industrial talks Ingredients Lab Equipment Logistics & Distribution Manufacturing Market Outsourcing Packaging Quality / GMP Regulation Safety --> Guía de empresas Guía online Productos Proyectos Servicios Últimos regis
%PDF-1.5 %���� 17 0 obj > endobj 18 0 obj > endobj 20 0 obj > stream x��[w|U��s��M�$!�DB (�)A�"%B"RT �`��'" R H��t��T��)�0�ZH�g���7 ��&����G����/{vggw��7���5���% FPJSJ�4 =�L�F����wI��$t� ] ~]��&�0�{��ϖ�n;�琾�������IZܤT�yk���>��a6���"7�ͨ�T9'2I8���w�a��j�D�[��W��s�n`�#�U\��P�+�m�"���\p�M���R\��;(]ŦO$��X� �` ���h���S�A g���ʷi�L�B�>��[���IC^S�w 7�jr(�Z,Q��J��Q�$��T(�>3o{�N& �m��ޥkC����8d�G�z$�L[�@����Wwqb�]��XL��ꬊ�Ժ���N�D+�(��>i�;��]o0��C1��{�K��2K�4�4ΒأfB:rv�C1I3�+��XN&��"�.� DH8�� �i �\ ~o)�EoR.���=H��)��κ���!0�A0�PL�|4�UQ}1G_���1����.d
Vascarta Inc Highlights VAS-101 Progress in Osteoarthritis and Sickle Cell Disease | Longevity Biotechnology Association posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn
Vascarta announces phase 1 results of VAS-101 administered sublingually in sickle cell disease patients | pharmapress.co.uk Linkedin X Website Youtube Latest news Drug Discovery and Development Clinical Trials Insights Funding & Finance Pharma Delivery and Supply Chain Conferences and events Pharma in Healthcare Pharma Technology and Automation Pharma Lab Pharma Lab news Pharma Lab articles Pharma Lab products Videos Conferences and Events Company Directory Publications Search Linkedin Linkedin Twitter Twitter Youtube Youtube Subscribe to DDD newsletter 27 June 2026 Contact us About us Li … aluate novel amylin receptor agonist VK3019 in healthy adults Reprocell submits application for manufacturing and marketing approval in Japan for stem cell therapy Stemchymal for spinocerebellar ataxia Load more Popular categories Drug Discovery & Development 121 Clinical Trials Insights 101 Pharma Lab news 78 Finance, mergers and appointments 64 Pharma in Healthcare 50 Technology and Automation 32 Conferences/events archive 31 Company Directory 24 Conferences and events
Vascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery … of this study demonstrate that, in people with knee osteoarthritis, the topical application of VAS-101 reduced knee pain within 28 days, with clinically meaningful improvements occurring in approximately 40% of participants. VAS-101 may represent a promising option for individuals experiencing knee osteoarthritis." Study Design The randomized, double-blind, placebo-controlled trial enrolled 60 adults aged 45–75 with knee osteoarthritis. Participants applied either 0.1 mL VAS- … 1 for osteoarthritis with the anticipated filing of an Investigational New Drug Application to the United States Food & Drug Administration later this year." About Knee Osteoarthritis Knee osteoarthritis is a degenerative joint condition affecting millions of adults worldwide. It is characterized by chronic pain, stiffness, reduced mobility, and progressive deterioration of joint cartilage. About VAS-101 VAS-101 is an investigational topical curcumin formulation dev … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.6 %���� 1108 0 obj > endobj 1144 0 obj >/Filter/FlateDecode/ID[ ]/Index[1108 135]/Info 1107 0 R/Length 159/Prev 3281707/Root 1109 0 R/Size 1243/Type/XRef/W[1 3 1]>>stream h�bbd```b``} "����8,b "��ŵA${ �dK� �q& �,�� >stream hތRKk�P>�Io3mhs�[ �N��U��P]����. � �h Ѕ �����;�⸱V(.Ņ�q�:����h�� �"�B�ܛy�"^�w��9�\P����7��~,�TT�τ)�����}l(�y���������s];��Ե�R�k���ٷ ��㣻�/�ܟ��#SQ��Йi�zA��Fl��2�#�L��W�����P4m� ���yƷe�-�Q���/�_Ⱥo������[��U��e%��i6.CCI�XF���2_]Bn.�E���ȔK�B9�������=��} �)r�� ��3��l6���G��dD�� D�fb�a����/�ܟ�S�ɐސ�@:- ���S�������� �}0�c�&|? f )�ҙ�I�? … fD�;4Nt���0����� �alp8Ec� ��B���*U+$��oT�� ��}Y�Ey���}��{� egfɓw��� >stream application/postscript NatPortfolio_inline_rgb Paul Young Adobe Illustrator CS6 (Windows) 2021-01-15T15:23:29+05:30 2021-01-15T15:23:29+05:30 2021-01-15T15:23:29+05:30 default uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:738991791757EB11B2C8BF536918004B xmp.iid:738991791757EB11B2C8BF536918004B uuid:6e11b642-7c5f-434d-b089-4f2a72879dba xmp.did:fd0ee465-d7db-4d00-a4fc-614ffd36c4fc default converted … f2a72879dba xmp.did:fd0ee465-d7db-4d00-a4fc-614ffd36c4fc default converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to … t to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator Acrobat Distiller 10.1.16 (Windows) 1 296.999959 210.000102 Millimeters Black endstream endobj 1135 0 obj >stream Adobe Illustrator CS6 (Wind … 20-05-01T13:20:14+05:30 1 222.750000 42.750000 Pixels Cyan Magenta Yellow Black application/postscript CROSSMARK_Color_txt_230x50.eps Rakesh Masih Acrobat Distiller 10.1.16 (Windows) xmp.did:44754A64808BEA118366C8EA238ECFDC xmp.iid:44754A64808BEA118366C8EA238ECFDC uuid:cc8e75c1-b853-4070-befd-c7314206c649 uuid:ac4930d5-7a1b-4f38-b04d-8083f4a11bb8
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Congratulations to... - Albert Einstein College of Medicine Facebook Log In Albert Einstein College of Medicine's Post Albert Einstein College of Medicine July 8, 2025 · Shared with Public Congratulations to Einstein's Joel Friedman, M.D., Ph.D. Vascarta, Inc, an Einstein start-up company formed to advance his innovation has advanced his compound for treating sickle cell disease toward clinical trials. The National Heart, Lung, and Blood Institute of the National Institutes of Health has signed a trial agreement with Vascarta to perform a phase 1 clinical study on topical curcumin ge
All Banking & Financial Services News and Press Releases from PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Mul … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 23 --> 23 24 --> 24 25 --> 25 26 --> 26 27 --> 27 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected. Items per page: 25 per page 50 per page 75 per page 100 per page Contact PR Newswire Call PR Newswire at 888-776-0942 from 8 A … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Expert Wellness Advice and Health Tips by Vascarta Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us 201-572-2484 Make a call [google-translator] Advices Home Portfolio Dev Marketome June 2021 Cosmetic Testing Project info It is a long-established fact that a reader will be distracted by the readable content of a page when looking at its layout. Date 14 August 2023 Client Nik Morison Category Pathology Project Pilelabs Service Lab Technician Ti-facebook Twitter Youtub
Vascarta Appoints Former Johnson & Johnson Executive Richard Serbin as Chief Strategy Officer | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architectu
Vascarta's topical curcumin improves health in aged animals | Longevity Biotechnology Association posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Contin … curcumin’s therapeutic potential and pave the way for further research into its application for aging-related conditions in humans. This groundbreaking work was led by LBA members Joel Friedman , Chief Scientific Officer and Board Member of Vascarta, Richard Prince , Chairman, CEO & President of Vascarta, and the dedicated Vascarta team. Access the full paper - https://lnkd.in/esK4gqZ6 #AgingResearch #Geroscience #Curcumin #TopicalTherapeutics #Bioavailability #VascularHe
Accurate Vascular Lab Testing Solutions from Vascarta Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us 201-572-2484 Make a call [google-translator] Tests With Staff Home Portfolio Tests With Staff Project Details Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has
Vascarta - 2026 Company Profile, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corporates
Vascarta Announces Addition of Richard Serbin to Leadership Team Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Galle … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Newsroom, Media Highlights & Press Releases | Vascarta It is a long established fact that a reader of a page when looking at its layout. Book Now Error: Contact form not found. 201-572-2484 [email protected] Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us Search for: Search Media Home Media Title Focus Type Year Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients Sickle Cell Disease Press Release; Published
Vascarta, Inc. | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Vascarta, Inc. Vascarta Inc. is a pharmaceutical company that has developed a patented topical/transdermal delivery platform aimed at improving the bioavailability of drugs, particularly curcumin, a compound known for its anti-inflammatory and antioxidant properties. The company focuses on addressing unmet medical needs through innovative formulations that enhance therapeutic efficacy and patient outcomes. Industries health-care medical pharmaceutical Nr. of Emp … n development Collaborative licensing, acquisition, or research partnerships to apply the transdermal delivery platform to partner molecules, alone or combined with botanicals, and to conduct preclinical or clinical studies. Provision of formulation for academic research Supply of transdermal formulation variants to academic collaborators for preclinical studies. Prescription fulfillment and patient support via compounding pharmacy Dispensing of the topical/transdermal curcum
Proprietary Patents in Vascular Science | Vascarta It is a long established fact that a reader of a page when looking at its layout. Book Now Error: Contact form not found. 201-572-2484 [email protected] Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us Search for: Search Patents Home Patents Vascarta has pursued intellectual property protection for its key assets. The Vascarta technology platform is based on a proprietary formulation with broad applications in tra … ood storage and transfusion. U.S. Patent No. 12,059,493 and pending U.S. Patent Application No. 18/051,266 cover the formulation, which includes an effective amount of a nitric oxide (NO) booster such as a curcuminoid or flavonoid dissolved in a polyol solvent. U.S. Patent No. 11,786,456, along with U.S. Patent Application Nos. 18/487,668 and 18/794,030, are directed to methods of treating various diseases and conditions using the formulation. These conditions include renal f … and a method for transfusing it into a subject in need. Divisional U.S. Patent Application No. 18/944,844 is directed to an ex vivo biological material sample comprising a biological material admixed with the formulation. It also includes claims to methods of transfusing the blood and treating disease via administration of the treated biological material sample. Corresponding patent applications covering the formulation and its medical and transfusion related uses have been
Partner With Us to Advance Health Technologies | Vascarta It is a long established fact that a reader of a page when looking at its layout. Book Now Error: Contact form not found. 201-572-2484 [email protected] Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us Search for: Search Partnering Home Partnering Vascarta seeks strategic partners to help develop and commercialize its unique technologies. We are dedicated to bringing to market New Molecular Entities (NMEs)
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Scientist.com Innovation Hub | Trends & Innovations Across the Pipeline --> --> --> --> Skip to Main Content Clients Our Platform Manage life science work from request to results Vendor Network Guided Buying Workflow Automation Regulatory Compliance Actionable Insights Your Pipeline Unified platform designed to support the full lifecycle of drug development Discovery & Preclinical Clinical PharmDev & Manufacturing Medical & Commercial AI Capabilities The only AI orchestration engine built for life sciences Source, Manage, and Scale External Research Request a Demo Request a Dem … e (RWE) Safety & Pharmacovigilance Toxicology Medical Communications Cancel Apply Email address Subscribe I would like to receive the monthly Scientist.com newsletter. I agree to receive email communication from Scientist.com and accept the data privacy statement. By submitting your information, you agree to our Terms of Service and Privacy Policy . You can opt out anytime. Blog Accelerating the Design–Build–Test–Learn Cycle for AI-Driven Antibody Discovery Read blog … e (RWE) Safety & Pharmacovigilance Toxicology Medical Communications Cancel Apply Email address Subscribe I would like to receive the monthly Scientist.com newsletter. I agree to receive email communication from Scientist.com and accept the data privacy statement. By submitting your information, you agree to our Terms of Service and Privacy Policy . You can opt out anytime. © 2026 Scientist Cookies Policy Global Privacy Policy We use cookies for various purposes including
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Vascarta: Top Pharmaceutical Company in Summit, NJ It is a long established fact that a reader of a page when looking at its layout. Book Now Error: Contact form not found. 201-572-2484 [email protected] Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us Search for: Search Home // Our Mission Advancing Treatments for Pain and Inflammation Advance and market novel patent-protected treatments for chronic inflammatory diseases - such as Sickle Cell Disease, Osteoarthri … s Safety Extensive scientific studies confirm curcumin gel’s safety for topical application with no reported adverse effects. Read More Pre-Clinical Validation Comprehensive pre-clinical studies highlight curcumin gel’s potential in addressing endothelial dysfunction. Read More Treatments with Curcumin-Gel Innovative formulations show enhanced curcumin absorption, improving red blood cell health and stability. Read More Results Results indicate measurable improvement in
About Us | Learn About Vascarta | Our Vision & Purpose It is a long established fact that a reader of a page when looking at its layout. Book Now Error: Contact form not found. 201-572-2484 [email protected] Home About Leadership Team SCD Scientific Advisors Scientific Collaborators Business Consultants Clinical Research Pre-Clinical Research Patents Partnering FAQs Media Contact Us Search for: Search About Home About About Us Moving Medicine Forward, Smartly Vascarta is a clinical-stage pharmaceutical company dedicated to improving the effectiveness of established therapies through thr … rong preclinical outcomes in Brain Cancer and Pancreatic Cancer support broader application in oncology. Martin Dummy Chairman and founder Leadership Team Richard Prince, PhD – Chairman, CEO & President Dr. Richard Prince’s successful 40-year career in life science includes multivariate management & executive roles, spanning startups to commercial companies, small molecule and large molecule programs, as well as being on both the service and product secto … pecific roles include Chief Financial Officer, General Counsel, Venture Capital Fund Manager and serving on multiple hospital boards. SCIENTIFIC ADVISOR Dr. Scott Braunstein, M.D. – Scientific Advisor Dr. Scott Braunstein brings over 30 years of biotechnology and pharmaceutical industry experience. Previously he served as Chairman and CEO of Marinus Pharmaceuticals, Inc., a commercial-stage company focused on rare forms of epilepsy, until acquired by Immedica Pharma AB. … rmaceutical company; and Portfolio Manager at the J.P. Morgan Global Healthcare Fund. Dr. Braunstein has been an operating partner at Aisling Capital since 2015. He currently serves on the board of directors for several companies. He received an M.D. from the Albert Einstein College of Medicine. SICKLE CELL DISEASE SCIENTIFIC ADVISORS Nirmish Shah, M.D. Nirmish Shah is an Associate Professor of Medicine & Pediatrics. He is the Director of Duke’s sickle cell transition pro … obtained his medical degree from the American University of the Caribbean, his residency & fellowship was at East Carolina University and Duke University School of Medicine. Payal Desai, M.D. Dr. Desai is the director of the Adult Sickle Cell Enterprise at Atrium Health Levine Cancer Institute. She has received multiple grants and funding fo
Vascarta Announces Addition of Richard Serbin to Leadership Team - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Vascarta Announces Addition of Richard Serbin to Leadership Team June 9, 2026 | 2 min read Twitter LinkedIn Facebook Email Print Richard Serbin brings leadership in strategic planning and regulatory affairs. SUMMIT, N.J. , June 9, 2026 /PRNewswire/ -- Vascarta Inc. is proud to announce the addition of Ric … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vascarta and CUNY Report Preclinical Breakthrough in Glioblastoma Treatment - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Vascarta and CUNY Report Preclinical Breakthrough in Glioblastoma Treatment November 11, 2025 | 3 min read Twitter LinkedIn Facebook Email Print SUMMIT, N.J. , Nov. 10, 2025 /PRNewswire/ -- Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly thera … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vascarta Announces Completion of Phase 1 Clinical Trial of VAS-101 for the Treatment of Osteoarthritis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell a … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Vascarta Announces Completion of Phase 1 Clinical Trial of VAS-101 for the Treatment of Osteoarthritis September 30, 2025 | 2 min read Twitter LinkedIn Facebook Email Print SUMMIT, N.J. , Sept. 29, 2025 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative tre … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Novel Transdermal Curcumin (VAS-101) Improves Cardiac Mitochondrial Function in Sickle Cell Disease Mouse Model, New FDA Led Study Shows - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Novel Transdermal Curcumin (VAS-101) Improves Cardiac Mitochondrial Function in Sickle Cell Disease Mouse Model, New FDA Led Study Shows December 3, 2025 | 4 min read Twitter LinkedIn Facebook Email Print SUMMIT, N.J. , Dec. 3, 2025 /PRNewswire/ -- Vascarta Inc., is pleased to share results from a new stu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vascarta and CUNY collaborate to improve chemotherapy efficacy and safety - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinio … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Vascarta and CUNY collaborate to improve chemotherapy efficacy and safety January 14, 2025 | 3 min read Twitter LinkedIn Facebook Email Print SUMMIT, N.J. , Jan. 13, 2025 /PRNewswire/ -- Vascarta has obtained the exclusive rights to a novel method of creating more effective cancer therapies with fewer sid … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business J … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Vascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis April 2, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Novel Transdermal Curcumin Formulation Demonstrates Pain Reduction and Improved Quality of Life in Phase 1b Clinical Trial … of this study demonstrate that, in people with knee osteoarthritis, the topical application of VAS-101 reduced knee pain within 28 days, with clinically meaningful improvements occurring in approximately 40% of participants. VAS-101 may represent a promising option for individuals experiencing knee osteoarthritis." Study Design The randomized, double-blind, placebo-controlled trial enrolled 60 adults aged 45–75 with knee osteoarthritis. Participants applied either 0.1 mL VAS- … 1 for osteoarthritis with the anticipated filing of an Investigational New Drug Application to the United States Food & Drug Administration later this year." About Knee Osteoarthritis Knee osteoarthritis is a degenerative joint condition affecting millions of adults worldwide. It is characterized by chronic pain, stiffness, reduced mobility, and progressive deterioration of joint cartilage. About VAS-101 VAS-101 is an investigational topical curcumin formulation dev … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Transdermal Curcumin Yields Promising Data for Sickle Cell Sufferers Presented at Annual American Society of Hematology Conference in San Diego, California - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developme … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Transdermal Curcumin Yields Promising Data for Sickle Cell Sufferers Presented at Annual American Society of Hematology Conference in San Diego, California December 11, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Vascarta Inc. announced new research findings presented at the American Society of … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Highly bioavailable transdermal gel from Vascarta may offer a safe and effective new way to treat sickle cell disease - presentation at American Society of Hematology Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Sear … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Highly bioavailable transdermal gel from Vascarta may offer a safe and effective new way to treat sickle cell disease - presentation at American Society of Hematology Conference December 11, 2024 | 4 min read Twitter LinkedIn Facebook Email Print SAN DIEGO , Dec. 10, 2024 /PRNewswire/ -- Vascarta Inc. ("V … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Patented transdermal drug candidate from Vascarta may offer a convenient & cost-effective way to treat sickle cell disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Patented transdermal drug candidate from Vascarta may offer a convenient & cost-effective way to treat sickle cell disease February 18, 2025 | 5 min read Twitter LinkedIn Facebook Email Print SUMMIT, N.J. , Feb. 18, 2025 /PRNewswire/ -- An article in the Proceedings of the National Academy of Sciences … zed sickle cell mice. In some instances, the reduction occurred within hours of application of the drug candidate. There was a substantial reduction in mast cell activation, a process that directly contributes to the onset and persistence of chronic pain. The topical treatment also resulted in a decrease in multiple markers of inflammation including interleukins 2, 4, and 6 (IL-2, IL-4, IL-6), interferon, and other inflammatory markers. Moreover, red blood cell stability and … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vascarta commences a Phase I clinical study of VAS101 in osteoarthritis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Vascarta commences a Phase I clinical study of VAS101 in osteoarthritis March 19, 2025 | 4 min read Twitter LinkedIn Facebook Email Print SUMMIT, N.J. , March 18, 2025 /PRNewswire/ -- A 60-patient, randomized, double-blind, placebo-controlled phase I clinical study of VAS101 (topical curcumin gel) i … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin